Cyclophosphamide
Batten Disease
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Batten Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Aavrh.10Cucln2 Weill Medical College of Cornell University | Phase 1/2 | CCC |
Human Placental Derived Stem Cell New York Medical College | Phase 1 | CC |
Duoc-01 Joanne Kurtzberg, MD | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →